Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.62 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18328442 | 0.92 | EPHX2 (0.72) | EPHX2FAAHSTSTRPV1CNR1 | |
| SCHEMBL14102773 | 0.92 | EPHX2 (0.72) | EPHX2FAAHSTSTRPV1CNR1 | |
| SCHEMBL12980257 | 0.92 | EPHX2 (0.72) | EPHX2FAAHSTSTRPV1CNR1 | |
| SCHEMBL14102656 | 0.86 | EPHX2 (0.65) | EPHX2FAAHSTSTRPV1CNR1 | |
| SCHEMBL15915089 | 0.86 | HPGD (0.67) | EPHX2FAAHSMN1; SMN2LMNAHTT | |
| SCHEMBL31412952 | 0.84 | FAAH (0.76) | EPHX2FAAHTRPV1CNR1CNR2 | |
| SCHEMBL14102635 | 0.82 | EPHX2 (0.59) | EPHX2FAAHSTSTRPV1CNR1 | |
| SCHEMBL3809498 | 0.81 | EPHX2 (0.84) | EPHX2FAAHSTSTRPV1CNR1 | |
| SCHEMBL8468019 | 0.81 | EPHX2 (0.74) | EPHX2FAAHLMNACNR1HPGD | |
| SCHEMBL2092775 | 0.80 | CYP3A4 (0.61) | EPHX2LMNAHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | disclosed |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | PHARMA CINQ, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2021-06-03 | — | — | US | disclosed |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | WELLSTAT THERAPEUTICS CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3632426-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2950649-B1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190194193-A1 | AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20180298000-A1 | AMINOQUINOLINE COMPOUNDS HAVING ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2018-10-18 | — | — | US | disclosed |
| US-10030015-B2 | Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-07-24 | — | — | US | disclosed |
| CN-104968200-B | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | 维尔斯达医疗公司 | 2018-03-06 | — | — | CN | disclosed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | NOD1, NLRP3, AADAC | EPHX2 4031/4885FAAH 3346/4885STS 3487/4885 |
| US-20180298000-A1 | AMINOQUINOLINE COMPOUNDS HAVING ANTICANCER ACTIVITY | MYC, AAAS, ASNS | EPHX2 3820/4885FAAH 3093/4885STS 4352/4885 |
| US-20190194193-A1 | AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AAAS, AADAC, NFKBIA | EPHX2 4356/4885FAAH 3574/4885STS 3921/4885 |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | EPHX2 3375/4885FAAH 2992/4885STS 3818/4885 |
| US-10030015-B2 | Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | AADAC, CASP1, AAAS | EPHX2 3375/4885FAAH 2992/4885STS 3818/4885 |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | EPHX2 3375/4885FAAH 2992/4885STS 3818/4885 |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | NOD1, NLRP3, AADAC | EPHX2 4031/4885FAAH 3346/4885STS 3487/4885 |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | AAAS, AADAC, NFKBIA | EPHX2 4356/4885FAAH 3574/4885STS 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.